住院患者抗肿瘤药物的用药分析  

Analysis of antitumor drugs

作　　者：陈海滨[1] 刘萍[1] 倪世静[2] 

机构地区：[1]解放军总医院药品保障中心中药房,北京100853 [2]海南医学院药学院

出　　处：《中国医药》2011年第12期1470-1472,共3页China Medicine

摘　　要：目的分析解放军总医院住院患者抗肿瘤药物的应用情况及其发展趋势，为临床科室合理用药提供依据。方法对我院住院患者2007-2009年抗肿瘤药物的用药金额、分类、用药频度（DDDs）等统计分析。结果我院住院患者2007、2008、2009年抗肿瘤药的用药金额分别为9170．3万元、13601万元、18749．8万元，呈快速增长趋势；多西他赛虽然DDDs较小，但增长较快，销售额3年稳居首位；单抗类抗肿瘤药销售金额呈快速增长趋势；中成药的DDDs构成比最高；抗代谢药消耗金额构成比相对稳定；抗肿瘤抗生素类、烷化剂和激素类在整个抗肿瘤药中所占的构成比较小并且逐年呈下降趋势。结论目前我院住院患者抗肿瘤药物使用基本合理，中成药在我院肿瘤治疗方面起到了很好的辅助作用。新型高效、低毒、靶向类的药物及植物药将成为以后抗肿瘤治疗的主要趋势。Objective To evaluate the application and tendency of antitumour drugs used in inpatients to provide references for rational use of drug. Methods The data was statistically analyzed regarding consumption sum, classification and DDDs from 2007 to 2009. Results The consumption sum of the antitumour drugs was 9. 190, 14.408 and 18. 751 millions RMB respectively, with a tendency of increase. Docetaxel ranked the first place in terms of consumption sum during three years and the consumption sum increased synchronously, but the DDDs of docetaxel was low. The consumption of the monoclonal antibodies shows a rapid upward trend. The proportion of the DDDs of the Chinese patent medicine in total was tremendous. The constituent ratio of antimetabolites in total did not change greatly. The constituent ratios of the antibiotics, alkylating agents and hormones of antineoplastic were small and decreased year by year. Conclusions The use of antitumor drug in inpatients of our hospital is basically rational. The new antitumor of the high performance, low poision and target will become the predominant methods in tumor therapy in the future.

关 键 词：抗肿瘤药物 限定日剂量 用药金额 住院患者 

分 类 号：R979.1[医药卫生—药品]